In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), ...
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...
Trump administrations pro-corporation policies boost healthcare M&A prospects Healthcare investment outlook improves as Trump ...
Roche's GLP-1 drug candidates, acquired from Carmot Therapeutics, are crucial for its valuation, with promising early-stage results but some concerning side effects. The Poseida deal, though ...
Poseida Therapeutics, Inc. (NASDAQ:PSTX), a biotechnology company specializing in biological products with a market capitalization of $929 million, announced today that it has completed a significant ...
Hosted on MSN16d
European stocks mostly lower; German data points to weak economyInvesting.com - European stock markets closed mostly down Wednesday, with investors fretting following the release of ...
Inc.'s subsidiary Blue Giant Acquisition Corp. has successfully completed a tender offer for all outstanding shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX). Roche's offer included $9.00 per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback